Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 4/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567051 | 1.00 | TAAR1 (0.67) | TAAR1MAOAHRH1MAOBLOXL2 | |
| SCHEMBL29263666 | 1.00 | TAAR1 (0.67) | TAAR1MAOAHRH1MAOBLOXL2 | |
| SCHEMBL7005631 | 1.00 | TAAR1 (0.67) | TAAR1MAOAHRH1MAOBLOXL2 | |
| SCHEMBL3706426 | 0.98 | TAAR1 (0.70) | TAAR1MAOAHRH1MAOBLOXL2 | |
| Hydrochloric Acid SCHEMBL7393435 | 0.95 | TAAR1 (0.67) | TAAR1MAOAHRH1MAOBLOXL2 | |
| SCHEMBL1319643 | 0.91 | TAAR1 (0.73) | TAAR1MAOAHRH1MAOBLOXL2 | |
| Hydrochloric Acid SCHEMBL2149447 | 0.88 | TAAR1 (0.70) | TAAR1MAOAMAOBLOXL2HTR2A | |
| SCHEMBL10571903 | 0.88 | TAAR1 (0.59) | TAAR1MAOBLOXL2AOC3 | |
| SCHEMBL9350714 | 0.88 | MAOA (0.71) | MAOAHRH1MAOBHTR2A | |
| SCHEMBL3680378 | 0.85 | MAOA (0.75) | TAAR1MAOAHRH1MAOBHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | TAAR1 61/4885MAOA 27/4885HRH1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.